Literature DB >> 32337654

Evaluation of Mogroside V as a Promising Carrier in Drug Delivery: Improving the Bioavailability and Liver Distribution of Silybin.

Yuqin Luo1, Chunyan Gong2, Mingmin Wei1, Yi Chen1, Ting Song1, Chunyong Wu3, Liying Mo4,5, Junying Zhang6,7.   

Abstract

The objective of this work was to investigate the capacity of mogroside V (MOG-V), a food additive, as a novel carrier to improve the bioavailability and liver distribution of silybin (SLY). Solid dispersion particles (SDPs) of SLY/MOG-V were prepared utilizing the solvent evaporation method. The physicochemical characterizations of SDPs were evaluated by using dynamic light scattering (DLS), differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD) measurements. DLS results demonstrated the formation of nanoparticles (206 nm) of SDPs in water. DSC and PXRD analysis revealed that SLY was in amorphous form or molecularly dispersed in SDPs. SDPs also exhibited a major increase in both dissolution rate and saturation solubility, as evidenced by a 1931-fold improvement (2201 μg/mL) in solubility compared with pure SLY (1.14 μg/mL). The pharmacokinetic study in rats showed that oral absorption of SLY/MOG-V SDPs was dramatically increased. The mean value of AUC until 12 h for SLY/MOG-V SDPs (27,481 ng·min/mL) was 24.5-fold higher than that of pure SLY (1122 ng·min/mL). In vivo tissue distribution experiment in mice confirmed that the major distribution tissue was changed from lungs to liver after SLY was loaded into MOG-V. In addition, even orally administrated to mice at a high dose (4.2 g/kg), MOG-V exhibited no undesirable effect on the plasma glucose concentrations. Thus, MOG-V may have the applicability to serve as an ideal excipient for solubilization or as a novel liver targeting carrier for the delivery of SLY.

Entities:  

Keywords:  bioavailability; liver distribution; mogroside V; solid dispersion particles; solubility

Mesh:

Substances:

Year:  2020        PMID: 32337654     DOI: 10.1208/s12249-020-01645-9

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  2 in total

1.  Silibinin Schiff Base Derivatives Counteract CCl4-Induced Acute Liver Injury by Enhancing Anti-Inflammatory and Antiapoptotic Bioactivities.

Authors:  Rong Xu; Siyan Qiu; Jie Zhang; Xiaoli Liu; Ling Zhang; Haizhu Xing; Min You; Man Wang; Yuting Lu; Peng Zhang; Jing Zhu
Journal:  Drug Des Devel Ther       Date:  2022-05-16       Impact factor: 4.319

2.  The Protective Effects of Mogroside V Against Neuronal Damages by Attenuating Mitochondrial Dysfunction via Upregulating Sirtuin3.

Authors:  Hanjiang Luo; Caixia Peng; Xiaofeng Xu; Yuntao Peng; Fang Shi; Qinghua Li; Jianghui Dong; Min Chen
Journal:  Mol Neurobiol       Date:  2022-01-18       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.